NeuroBo Pharmaceuticals, Inc. (NRBO)
| Market Cap | 66.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -28.27M |
| Shares Out | 22.29M |
| EPS (ttm) | -1.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 27 |
| Last Price | $2.97 |
| Previous Close | $2.97 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 2.95 |
| Day's Range | 2.83 - 3.07 |
| Day's Volume | 229,234 |
| 52-Week Range | 2.70 - 7.61 |
Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...
Life Clips (LCLP) stock is falling on Tuesday following an update from the battery company about its recent business announcements. The post LCLP Stock: 10 Reasons Why Penny Stock Battery Maker Life Cli...
Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...
Neurobo Pharmaceuticals (NRBO) stock is on the rise Tuesday as retail traders take a liking to the biotechnology company. The post NRBO Stock: 6 Things to Know About NeuroBo Pharma as Retail Investors S...
BOSTON, July 12, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapie...
BOSTON, May 17, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies...
BOSTON, April 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapi...
Wall Street recommends buying shares of NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) and Windtree Therapeutics Inc (NASDAQ:WINT), even though these two securities have shown poor performance over the prior...
BOSTON, March 24, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has received approval of an amendment to its Continge...
BOSTON, Jan. 21, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced private placement of a...
BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a priva...
NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...
BOSTON, Aug. 11, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.
BOSTON, June 16, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...
About NRBO
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an ac... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol NRBO |
Analyst Forecasts
According to one analyst, the rating for NRBO stock is "Buy" and the 12-month stock price forecast is 16.00.